Close Menu

CHICAGO (GenomeWeb) – Two next-generation precision oncology drugs, one an EGFR inhibitor and an ALK inhibitor, have shown to be far more effective against advanced non-small cell lung cancer than older drugs in their class.

At the American Society of Clinical Oncology's annual meeting, researchers presented data from two head-to-head NSCLC trials, one comparing the first targeted EGFR inhibitor Iressa (gefitinib) against the next-generation dacomitinib; and another comparing the first ALK-inhibitor Xalkori (crizotinib) against newer agent Alecensa (alectinib).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Fluorescent proteins or self-labeling tags are invaluable tools for studying protein dynamics in living cells using fluorescence microscopy. However, quantitative imaging requires physiological levels of expression of the target protein of interest (POI), especially when stoichiometric interactions of the POI need to be investigated.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).